M&A In Latin America

M&A In Latin America: Americas Region

by Deloitte
Majority of M&A deals in Latin America during 2016 have been intra-regional. Industries such as financial services, consumer business, and energy and resources attracted many large investments in the region. Improving US markets may boost M&A in the region as it was the second largest investor during 2015-2016. However, weak oil and commodity prices may act as deterrents to M&A activity in the region. […] Read more

Plotting A New Course: The Impact Of Brexit On M&A Activity

Figure 1 UK M&A volumes and values (H1 2005 - H1 2016)

by Deloitte
In the aftermath of the EU referendum vote, the reaction from currency and stock markets has been swift. It is clear that Brexit has shaken investor confidence. However, M&A markets are typically driven by longer term decision making processes. Brexit has created uncertainties and some M&A plans are being put on hold. But we think the post-Brexit tumult creates opportunities as well. In the coming months we expect there will be both threats to M&A dealmakers and unique opportunities for them. […] Read more

The Deloitte M&A Index – 2016: Opportunities Amidst Divergence

M&A Index – 2016: Opportunities Amidst Divergence

by Deloitte
We are expecting 2015 to end with over $4 trillion worth of deals making it the highest for deal values since 2007. However, on a last-twelve-months (LTM) basis, there was a slowdown in the volume of transactions in the second half of 2015. Cross-border deals are a major feature of this M&A wave. More than $1 trillion worth of cross-border deals have been announced so far this year, of which a third were in the vibrant deal corridor between North America and Europe. […] Read more

Deal Tectonics: At The Fault Line Of Growth Goals And Competitive Pressures

Exhibit 1: Record M&A: a new normal

by Ernst & Young
As the specialty pharmaceutical sector sees its ability to pursue large acquisitions evaporate, long-promised organic growth from big pharma new drug launches has finally arrived. But a renewed focus on value-based pricing, staunch competition across key therapeutic battlefields and consolidating payer clout may weaken the industry’s ability to reach revenue targets for both new and legacy therapeutics. […] Read more

Dealing With Uncertainty: Strategies For Overcoming Compliance Risk And Regulatory Challenges In Cross-Border M&A

Figure 1 Pharmerging Markets

by Baker & McKenzie
When you look at the numbers, there’s no question why global pharmaceutical companies have set their sights on emerging markets for future growth. From 2012 to 2017, global pharmaceutical sales are expected to rise 13% in the “pharmerging markets,” compared to 2% for the top mature markets, according to the IMS Institute for Healthcare Informatics. […] Read more

Firepower Fireworks: Focus, Scale And Growth Drive Explosive M&A

Firepower fireworks Focus, scale and growth drive explosive M&A

by Ernst & Young
Record biopharma M&A exceeded US$200 billion in 2014, well over twice the average annual deal volume seen in the last decade, as companies used deal making to satisfy the strategic imperatives of increasing focus, scale and/or growth. A convergence of forces fueled the fireworks, including rising equity valuations, historically low interest rates and prodigious firepower. […] Read more

Strategic Alliances In Life Sciences: Are You Ready?

Figure 1 Challenges in the life science industry

by Deloitte
Life science companies have adopted a multi-track approach to cope with the current and anticipated drop in sales revenue, including cutting costs and staff; expanding business in emerging markets; recalibrating business models and research priorities; using real-world evidence and emphasising a product’s clinical, safety and economic impact to articulate their value proposition. Next to classic mergers and acquisitions (M&A) Strategic Alliances have proven to be a viable alternative in coping with these challenges. […] Read more

M&A Trends In Life Sciences And Health Care: Growth At The Global Intersection Of Change

Figure 1 Drivers of M&A activity

by Deloitte
Anyone witnessing the feverish deal-making that has swept through the global life sciences and health care industry recently might well conclude that mergers-and-acquisitions (M&A) activity has become the dominant force shaping the industry. According to Thomson Reuters, the global year-to-date value of deals in the life sciences sector alone was $600bn for July 2014, compared with $200bn for the same period last year. […] Read more

Are you sure you
want to log out?

Request a Brochure

Request a Brochure

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!

Book a Demo

Book a Demo

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!